[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Zhou M, Zhu Y, Wang L, Wang Y, Fu S, Min Z: Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases. Clin Transpl; 2006;:395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the epidemiographic features of urological malignancy in renal allograft recipients (RAR) in a single center METHODS: A retrospective analysis was made on 3150 patients who received renal allografts from June 1978 until the autumn of 2006 and anti-rejection treatment for at least 3 months.
  • RESULTS: Of the 3150 recipients, 33 (1.05%) developed malignancies, including 12 patients (0.38%; eight males and four females) with urological tumors and 21 patients with skin carcinoma, right liver lobular cystic adenocarcinoma, hepatocellular carcinoma, gastric cancer, colorectal carcinoma, ileocecal adenoma, lip cancer, nasopharyngeal carcinoma, Kaposi's Sarcoma, pulmonary lymphoma, and breast cancer.
  • The age at which the diagnosis was made ranged from 48 to 66 years with a mean of 58.3 +/- 4.6 years, and the mean course of immunosuppressive therapy ranged from 26 to 120 months with a mean of 62 +/- 18 months.
  • One of the 12 patients died soon after the diagnosis was made, and the remaining 11 patients received surgical resection.
  • The incidence of urological malignancy in renal allograft recipients (RAR) is about 10 times that found in the general population of Shanghai versus two times for other malignancies.
  • The occurrence of the malignancies in PAR seems to be closely related to the use of immunosuppressive agents. lmmunosuppression results in the weakening of immnuologic surveillance function, leading to mutation, aberration, and carcinogenesis.
  • Treatment includes early diagnosis, timely surgical resection, and reduction of immunosuppressive agents.
  • [MeSH-minor] Aged. Female. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365395.001).
  • [ISSN] 0890-9016
  • [Journal-full-title] Clinical transplants
  • [ISO-abbreviation] Clin Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


2. Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparén P, Tryggvadottir L, Weiderpass E, Kjaerheim K: Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol; 2009;48(5):646-790
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupation and cancer - follow-up of 15 million people in five Nordic countries.
  • We present up to 45 years of cancer incidence data by occupational category for the Nordic populations.
  • The study covers the 15 million people aged 30-64 years in the 1960, 1970, 1980/1981 and/or 1990 censuses in Denmark, Finland, Iceland, Norway and Sweden, and the 2.8 million incident cancer cases diagnosed in these people in a follow-up until about 2005.
  • All Nordic countries have a nation-wide registration of incident cancer cases during the entire study period.
  • For the present study the incident cancer cases were classified into 49 primary diagnostic categories.
  • Some categories have been further divided according to sub-site or morphological type.
  • The observed number of cancer cases in each group of persons defined by country, sex, age, period and occupation was compared with the expected number calculated from the stratum specific person years and the incidence rates for the national population.
  • For all cancers combined (excluding non-melanoma skin cancer), the study showed a wide variation among men from an SIR of 0.79 (95% confidence interval 0.66-0.95) in domestic assistants to 1.48 (1.43-1.54) in waiters.
  • Mesothelioma was the cancer type showing the largest relative differences between the occupations.
  • Outdoor workers such as fishermen, gardeners and farmers had the highest risk of lip cancer, while the lowest risk was found among indoor workers such as physicians and artistic workers.
  • Studies of nasal cancer have shown increased risks associated with exposure to wood dust, both for those in furniture making and for those exposed exclusively to soft wood like the majority of Nordic woodworkers.
  • For nasal adenocarcinoma, the SIR in males was as high as 5.50 (4.60-6.56).
  • Male waiters and tobacco workers had the highest risk of lung cancer, probably attributable to active and passive smoking.
  • Among women, tobacco workers and engine operators had a more than fourfold risk as compared with the lung cancer risk among farmers, gardeners and teachers.
  • The occupational risk patterns were quite similar in all main histological subtypes of lung cancer.
  • Bladder cancer is considered as one of the cancer types most likely to be related to occupational carcinogens.
  • Waiters had the highest risk of bladder cancer in men and tobacco workers in women, and the low-risk categories were the same ones as for lung cancer.
  • Chimney sweeps are exposed to carcinogens such as polycyclic aromatic hydrocarbons from the chimney soot, and hairdressers' work environment is also rich in chemical agents.
  • The highest risks of liver cancer were seen in occupational categories with easy access to alcohol at the work place or with cultural traditions of high alcohol consumption, such as waiters, cooks, beverage workers, journalists and seamen.
  • The risk of colon cancer has been related to sedentary work.
  • Colon cancer was one of the cancer types showing the smallest relative variation in incidence between occupational categories.
  • The occupational variation in the risk of female breast cancer (the most common cancer type in the present series, 373 361 cases) was larger, and there was a tendency of physically demanding occupations to show SIRs below unity.
  • Women in occupations which require a high level of education have, on average, a higher age at first child-birth and elevated breast cancer incidence.
  • In male breast cancer (2 336 cases), which is not affected by the dominating reproductive factors, there was a suggestion of an increase in risk in occupations characterised by shift work.
  • Night-shift work was recently classified as probably carcinogenic, with human evidence based on breast cancer research.
  • The most common cancer among men in the present cohort was prostate cancer (339 973 cases).
  • The present study shows that the risk of cancer, even under these circumstances, is highly dependent on the person's position in the society.
  • This publication is the first one from the extensive Nordic Occupational Cancer (NOCCA) project.
  • Subsequent studies will focus on associations between specific work-related factors and cancer diseases with the aim to identify exposure-response patterns.
  • In addition to the cancer data demonstrated in the present publication, the NOCCA project produced Nordic Job Exposure Matrix (described in separate articles in this issue of Acta Oncologica) that transforms information about occupational title histories to quantitative estimates of specific exposures.


3. Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW: Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP; 2008;9(2):197-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
  • CONTEXT: A recent meta-analysis suggests that the addition of oxaliplatin or cisplatin to gemcitabine can lead to improved survival in patients with advanced pancreatic cancer, especially those with a good performance status.
  • We present a case in which platinum-containing therapy was able to continue in a patient with metastatic pancreatic cancer following a hypersensitivity reaction to oxaliplatin, by switching to cisplatin after a negative intradermal skin test.
  • CASE REPORT: A 58-year-old gentleman with metastatic pancreatic adenocarcinoma received biweekly cycles of gemcitabine in combination with oxaliplatin.
  • During the fifth cycle, he experienced a grade 2 hypersensitivity reaction including erythema and lip numbness, for which he was medicated with antihistaminics and corticosteroids.
  • Literature review reveals scarce data of intradermal skin tests used to rechallenge cisplatin to patients with oxaliplatin hypersensitivity reaction, and our case is the first apparent example for a patient with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Drug Hypersensitivity / etiology. Organoplatinum Compounds / adverse effects. Pancreatic Neoplasms / drug therapy


Advertisement
4. Zhang Z, DuBois RN: Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene; 2001 Jul 27;20(33):4450-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous reports suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) decrease mortality from colorectal cancer.
  • We identified additional genes which are involved in different signaling pathways which regulate programmed cell death (Dynamin 2, Pdcd4 and LIP.1).
  • Additional studies are underway to determine the biological function of the novel genes that were identified.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Colonic Neoplasms / genetics. Cyclooxygenase Inhibitors / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Isoenzymes / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors. Nitrobenzenes / pharmacology. RNA-Binding Proteins. Sulfonamides / pharmacology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Apoptosis / genetics. Apoptosis Regulatory Proteins. Blotting, Northern. Cadherins / biosynthesis. Cadherins / genetics. Carrier Proteins / biosynthesis. Carrier Proteins / genetics. Catenins. Cell Adhesion. Cyclins / biosynthesis. Cyclins / genetics. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. DNA, Complementary / genetics. Dynamin I. Dynamins. GTP Phosphohydrolases / biosynthesis. GTP Phosphohydrolases / genetics. Gene Expression Profiling. Humans. Membrane Proteins. Phosphoproteins / biosynthesis. Phosphoproteins / genetics. Prostaglandin-Endoperoxide Synthases. Protein Biosynthesis. Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectal Neoplasms / genetics. Rectal Neoplasms / metabolism. Rectal Neoplasms / pathology. Signal Transduction / genetics. Substrate Specificity. Subtraction Technique. Tumor Cells, Cultured / drug effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11494140.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 47297; United States / NCI NIH HHS / CA / P0 CA77839; United States / NCI NIH HHS / CA / P30 CA68485
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Apoptosis Regulatory Proteins; 0 / CCNK protein, human; 0 / Cadherins; 0 / Carrier Proteins; 0 / Catenins; 0 / Cyclins; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / DNA, Complementary; 0 / FAT1 protein, human; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Nitrobenzenes; 0 / PCDH7 protein, human; 0 / PDCD4 protein, human; 0 / PPFIA1 protein, human; 0 / Phosphoproteins; 0 / Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA-Binding Proteins; 0 / Sulfonamides; 0 / delta catenin; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.5.1.50 / Dynamin I; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.5.5 / Dynamins
  •  go-up   go-down


5. Puleo S, Mauro L, Gagliano G, Lombardo R, Li Destri G, Petrillo G, Di Carlo I: Liver damage after transarterial chemoembolization without embolizing agent in unresectable hepatocellular carcinoma. Tumori; 2003 May-Jun;89(3):285-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver damage after transarterial chemoembolization without embolizing agent in unresectable hepatocellular carcinoma.
  • We analyzed the effects on hepatic function of a modified chemoembolization consisting of ethiodized oil (Lipiodol Ultra Fluid) and epirubicin without gelatine sponge (C-LIP).
  • METHODS: Of 90 patients with hepatocellular carcinoma observed from January 1995 to December 1999, 16 with a diagnosis of advanced (large or multifocal) disease underwent 19 C-LIP.
  • The 30th post-C-LIP day was considered as a checkpoint of the biochemical parameters for a possible hepatic failure.
  • Statistical analysis showed a significant finding of postoperative ascites (P = 0.035) and the effectiveness of C-LIP on neoplastic tissue by a decrease of alpha-fetoprotein values at 30 days (P = 0.067).
  • CONCLUSIONS: Transcatether arterial chemoembolization could represent an effective therapy against multifocal or advanced hepatocellular carcinoma, and its effectiveness is probably not decreased by using a modified procedure without embolizing agent (C-LIP).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver / drug effects. Liver Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Alanine Transaminase / blood. Antibiotics, Antineoplastic / administration & dosage. Aspartate Aminotransferases / blood. Epirubicin / administration & dosage. Female. Gelatin Sponge, Absorbable. Humans. Injections, Intra-Arterial. Iodized Oil / administration & dosage. Liver Cirrhosis / pathology. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908784.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


6. Ramchandani M, Brown AM, Rippin JW, Murray PI: Labial adenocarcinoma after treatment with cyclosporin a in a patient with panuveitis. Am J Ophthalmol; 2000 Jul;130(1):127-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Labial adenocarcinoma after treatment with cyclosporin a in a patient with panuveitis.
  • PURPOSE: To report a case of labial basal cell adenocarcinoma in a patient with uveitis on treatment with cyclosporin A.
  • A 73-year-old woman with panuveitis and retinal vasculitis presented with a lump on her lip after 52 months of treatment with cyclosporin A.
  • RESULT: Excision biopsy showed a labial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Cyclosporine / adverse effects. Immunosuppressive Agents / adverse effects. Lip Neoplasms / chemically induced. Panuveitis / drug therapy
  • [MeSH-minor] Aged. Female. Humans. Prednisolone / therapeutic use. Retinal Diseases / drug therapy. Retinal Vessels / drug effects. Vasculitis / drug therapy

  • Genetic Alliance. consumer health - Panuveitis.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11004277.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down






Advertisement